Publications
806
Citations
14,554
Est. group size
~2
Recurring co-author estimate
Active years
35
Publishing since 1992
Brian A. Walker studies the genetics and biology of multiple myeloma, a cancer of plasma cells in the bone marrow, and related blood cancers. Using genome sequencing and multi-omic approaches (combining data on DNA, gene activity, and epigenetics), the research aims to identify which genetic features make some cases high-risk, how patients respond to drugs, and potential new therapeutic targets. The work also includes clinical-oriented efforts such as consensus definitions of high-risk disease and monitoring residual disease from blood samples.
Publication output was fairly steady at 20-40 per year through 2022, then spiked sharply in 2023 before settling at a higher level in 2024-2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Abstract 5940: Chromosome-level phasing to resolve haplotypes using multiomic data in multiple myeloma reveals complex distal interactions between chromosomes that impacts epigenetic states and gene expression
Cancer Research · 2026
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Journal of Clinical Oncology · 2025
- Genomic landscape of multiple myeloma and its precursor conditions
Nature Genetics · 2025
- Evaluating the impact of <i>CRBN</i> mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
Blood · 2025
- A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes
Blood · 2025
- Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Journal of Clinical Oncology · 2025
- Whole Genome Sequencing of Cell-free DNA for Assessment of Minimal Residual Disease in High-Risk Smoldering Multiple Myeloma
HemaSphere · 2025
- Cyclin D1 Beyond the Cell Cycle: A New Role in t (11;14) MM
Clinical Lymphoma Myeloma & Leukemia · 2025
- Supplementary Table S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Figure S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Figure S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Spreadsheet S12 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Figure S17 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Spreadsheet S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Supplementary Spreadsheet S9 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
2025
- Blood×107
- Clinical Lymphoma Myeloma & Leukemia×10
- bioRxiv (Cold Spring Harbor Laboratory)×10
- Leukemia×9
- Blood Cancer Journal×9
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile